全文获取类型
收费全文 | 872篇 |
免费 | 33篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 26篇 |
妇产科学 | 5篇 |
基础医学 | 57篇 |
口腔科学 | 16篇 |
临床医学 | 43篇 |
内科学 | 148篇 |
皮肤病学 | 16篇 |
神经病学 | 54篇 |
特种医学 | 182篇 |
外科学 | 226篇 |
综合类 | 39篇 |
预防医学 | 20篇 |
眼科学 | 7篇 |
药学 | 20篇 |
中国医学 | 1篇 |
肿瘤学 | 49篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 11篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 15篇 |
2017年 | 15篇 |
2016年 | 9篇 |
2015年 | 16篇 |
2014年 | 17篇 |
2013年 | 25篇 |
2012年 | 41篇 |
2011年 | 40篇 |
2010年 | 37篇 |
2009年 | 34篇 |
2008年 | 40篇 |
2007年 | 29篇 |
2006年 | 33篇 |
2005年 | 37篇 |
2004年 | 20篇 |
2003年 | 16篇 |
2002年 | 21篇 |
2001年 | 16篇 |
2000年 | 22篇 |
1999年 | 15篇 |
1998年 | 27篇 |
1997年 | 43篇 |
1996年 | 32篇 |
1995年 | 26篇 |
1994年 | 19篇 |
1993年 | 18篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 21篇 |
1985年 | 14篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1982年 | 11篇 |
1981年 | 14篇 |
1980年 | 13篇 |
1979年 | 2篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 5篇 |
排序方式: 共有909条查询结果,搜索用时 15 毫秒
31.
32.
33.
BACKGROUND: Current ancillary markers for diagnosis in prostate biopsies include p63 and alpha-methylacyl-CoA racemase (AMACR). Annexin II (ANXII), a calcium and phospholipid binding protein, is lost in prostate cancer. AIMS: To investigate ANXII expression in order to assess its utility as a novel diagnostic marker in comparison to p63 and AMACR. METHODS: Using immunohistochemistry on six tissue microarrays, ANXII, p63, and AMACR expression was analysed from 210 radical prostatectomy cases. Staining was evaluated in benign and atrophic glands, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma. Separate scores were given for ANXII, AMACR and p63 expression. RESULTS: Diffuse cytoplasmic expression of ANXII correlated with p63 reactivity in basal cells. Benign glands were positive for ANXII in 286/292 cores (98%) and negative for AMACR in all 292 cores. HGPIN showed heterogeneous expression of AMACR and ANXII. A significantly larger proportion of HGPIN glands were correctly identified as ANXII negative than as positive for AMACR. ANXII loss in prostate cancer was found in 282/320 cores (88%) and correlated with positive AMACR expression (272/320 cores, 85%), which was not statistically significant. There was no statistically significant correlation between ANXII scores and the clinical parameters examined. CONCLUSIONS: Immunohistochemical staining for ANXII is a consistent and reliable marker of prostatic neoplasia. The findings of this study suggest the potential utility of ANXII as a diagnostic aid in prostate cancer histopathology. 相似文献
34.
Jaime O. Herrera-Caceres Gregory J. Nason Noelia Salgado-Sanmamed Hanan Goldberg Dixon T.S. Woon Thenappen Chandrasekar Khaled Ajib Guan Hee Tan Omar Alhunaidi Theodorus van der Kwast Antonio Finelli Alexandre R. Zlotta Robert J. Hamilton Alejandro Berlin Nathan Perlis Neil E. Fleshner 《BJU international》2020,125(4):525-530
35.
Douglas C. Cheung Neil Fleshner Shomik Sengupta Dixon Woon 《Translational andrology and urology》2020,9(6):3049
Pelvic lymph node dissection (PLND) is an important component in the staging and prognostication of prostate cancer. We performed a narrative review to assess the literature surrounding PLND: (I) the current guideline recommendations and contemporary utilization, (II) the calculation of patient-specific risk to perform PLND using available nomograms, (III) to review the extent of dissection, and its associated outcomes and complications. Due to the improved lymph node yield, better staging, and theoretical improvement in the control of micro-metastatic disease, guidelines have supported the use of (extended-) PLND in patients deemed to be at intermediate or high risk of lymph node involvement (often at a threshold of 5% on modern risk nomograms). However, in practice, real-world utilization of PLND varies considerably due to multiple reasons. Conflicting evidence persists with no clear oncological benefit to PLND, and a small, but important, risk of morbidity. Complications are rare, but include lymphoceles; thromboembolic events; and more rarely, obturator nerve, vascular, and ureteric injury. Furthermore, changing disease incidence and stage migration in the context of earlier detection overall have led to a decreased risk of nodal disease. The trade-offs between the benefits, harms, and risk tolerance/threshold must be carefully considered between each patient and their clinician. 相似文献
36.
37.
38.
Andrew G. Matthew Shabbir M. H. Alibhai Tal Davidson Kristen L. Currie Haiyan Jiang Murray Krahn Neil E. Fleshner Robin Kalnin Alyssa S. Louis B. Joyce Davison John Trachtenberg 《Quality of life research》2014,23(8):2309-2317
Purpose
To identify the health-related quality of life (HRQoL) domains that radical prostatectomy (RP) impacts most negatively and to define the recovery of these domains over 30 months of observation.Patients and methods
A total of 1,200 RP patients completed the Patient-Oriented Prostate Utility Scale-Psychometric (PORPUS-P; range 0–100, higher is better), a prostate cancer-specific HRQoL measure, prior to RP and at 0–3 (T1), 3–9 (T2), 9–18 (T3) and 18–30 (T4) months post-RP. HRQoL changes were examined using paired t tests and a mixed-effect growth curve model. Multivariable analyses were performed to investigate demographic and treatment factors predicting the change in HRQoL.Results
Mean baseline PORPUS-P score, 83.1, fell to 66.5 (p < 0.001) at T1. Over time HRQoL improved but did not return to baseline (T4 mean 76.4, p < 0.001). Domain analysis revealed that sexual function (p < 0.001), sexual drive (p < 0.001), energy (p = 0.001) and bladder control (p < 0.001) failed to return to baseline at T4. Sexual function demonstrated the greatest impairment overall. The multivariable model revealed Black men experienced greater losses in global HRQoL compared with White men (coefficient ?2.77, 95 % CI ?5.00 to ?0.54, p = 0.015). High baseline HRQoL, pro-erectile aid use and bilateral nerve-sparing were significantly associated with smaller reductions in HRQoL post-RP.Conclusion
Overall HRQoL, sexual drive, sexual function, energy and bladder control do not return to preoperative levels within 30 months post-RP. Black patients experience the greatest reductions in HRQoL. HRQoL losses may be ameliorated by use of pro-erectile aids. These findings help to identify at-risk patient populations and inform survivorship programs. 相似文献39.
40.